



A Correlational Study of Monosodium Urate Crystal Volume in Different Joints and Clinical Characteristics of Gout Patients: A Dual-Energy CT Study

Jiachun Zhuang ^{#1, 2}, Lin Liu ^{#3}, Yunyan Zi ⁴, Yingyi Zhu ², Lina Chen ⁵, Haijun Wu ^{2, *}

¹ Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong, P. R. China

² Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, Guangdong, P. R. China

³ Department of Radiology, Huizhou First People's Hospital, Huizhou 516001, Guangdong, P. R. China

⁴ Department of Medical Imaging, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Kunming 650102, Yunnan, P. R. China

⁵ CT Collaboration, Siemens Healthcare Ltd, Shanghai 200000, P. R. China

*Corresponding Author: Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, Guangdong, P. R. China. Email: 15876530875@163.com

These authors have contributed equally

Received: 9 October, 2024; Revised: 9 January, 2025; Accepted: 19 January, 2025

Abstract

Background: The spatial pattern of monosodium urate (MSU) crystal deposition is a hallmark of gout progression and contributes to the pathogenesis of associated comorbidities. However, the correlations between MSU crystal volume in the feet/ankle, knee, and hand/wrist joint sites and clinical features in gout patients remain unclear.

Objectives: This study aims to explore the spatial pattern of MSU crystal deposition and its potential relationship with associated comorbidities. Additionally, it evaluates the correlation between MSU crystal volume detected by dual-energy computed tomography (DECT) in different joints and clinical characteristics, including serum uric acid (sUA), glomerular filtration rate (GFR), and disease duration.

Patients and Methods: In this single-center study conducted from October 2017 to August 2023, 527 patients (mean age 49.0 ± 23.0 years) diagnosed with gout and confirmed MSU deposition via DECT were included. Spearman's rank correlation coefficient was used to assess relationships between sUA, gout duration, GFR, and MSU volumes in the foot/ankle, knee, and hand/wrist.

Results: Among the 527 patients, the median gout duration was 6.0 years. MSU crystals were most commonly found in the feet/ankles (84.8%), followed by knees (63.6%) and hands/wrists (28.8%). Gout duration positively correlated with MSU crystal volumes ($r = 0.32$, $P < 0.01$). MSU volumes in the feet/ankle and knee showed negative correlations with GFR ($r = -0.18$, $P < 0.01$; $r = -0.16$, $P = 0.03$, respectively), while no significant correlation was observed in hand/wrist volume ($r = -0.06$, $P = 0.55$). No significant associations were found between MSU volumes and sUA levels across all groups.

Conclusion: The MSU crystal burden negatively correlates with GFR but not with sUA levels. The volumes of MSU crystals in the ankle/foot and knee joints, along with the total volume of MSU crystals in the ankle/foot, hands/wrists, and knee joints, show a negative correlation with GFR and a positive correlation with disease duration. This indicates a need for further research on the relationship between MSU deposition and renal dysfunction in gout patients.

Keywords: Crystal Arthropathy, Gout, Dual-Energy Computed Tomography, Monosodium Urate

1. Background

Gout is the most common chronic arthritic inflammatory disease, characterized by the deposition

of monosodium urate (MSU) crystals, primarily influenced by elevated serum uric acid (sUA) levels (1, 2). Research consistently shows that the risk of gout increases with higher sUA levels (3). The MSU crystals

can form at physiological temperature and pH when urate concentrations exceed saturation levels (≥ 410 mmol/L, 6.8 mg/dL) (4). However, not all individuals with severe hyperuricemia develop acute inflammatory gouty arthritis, and the relationship between MSU crystal volume and uric acid concentration remains unclear (3).

Individuals with gout face heightened risks for various complications, including diabetes mellitus, cardiovascular disease, and chronic kidney disease (CKD) (5). A meta-analysis found that up to 24% of gout patients have stage 3 CKD or higher (6). Furthermore, gout is recognized as an independent risk factor for new-onset CKD (7). Declining glomerular filtration rate (GFR) may reduce uric acid excretion, thus promoting MSU crystal formation and complicating the relationship between kidney function and uric acid metabolism.

The MSU crystals predominantly deposit in the joints, with the first metatarsophalangeal (MTP) joint being the most frequently affected site, followed by the Achilles tendon and ankle (8). The location of urate deposition may correlate with hematologic markers such as sUA and GFR, reflecting distinct pathophysiological processes.

Recently, dual-energy computed tomography (DECT) has emerged as a validated noninvasive method for detecting MSU deposits, demonstrating a sensitivity of 0.87 and specificity of 0.84 (9). The DECT utilizes two X-ray sources to simultaneously acquire spiral data, and a specialized algorithm processes these images to differentiate between MSU and non-MSU deposits, enhancing its value as a diagnostic tool for gout.

2. Objectives

This study aimed to investigate the correlations of different volumes of MSU crystals at the feet/ankles, knees, and hands/wrists on DECT with clinical characteristics such as sUA, GFR, and disease duration.

3. Patients and Methods

3.1. Participants and Related Factors

This study was conducted at a single center, where demographic and clinical data were extracted from electronic health records during outpatient visits. This retrospective cross-sectional study was approved by the ethics committee of our hospital, and written informed consent was waived. We included patients presenting to the rheumatology outpatient department for gout flare

between October 2017 and August 2023, based on the criteria displayed in Figure 1.

Demographic factors (age, gender) and clinical characteristics of gout (disease duration, number of tophi deposition sites, MSU crystal volume across joints, total volume, sUA, GFR) were analyzed. Disease duration refers to the period from the initial acute flare to the hospital visit. The GFR was calculated using the modified Modification of Diet in Renal Disease equation: $c\text{-aGFR} (\text{mL/min per } 1.73 \text{ m}^2) = 186 \times \text{Pcr}^{-1.154} \times \text{age}^{-0.203} \times 0.742$ (if female) $\times 1.227$ (if Chinese) (10). The highest sUA and GFR values were analyzed per ACR/EULAR 2015 gout classification criteria (11).

A total of 527 patients were included, excluding those on urate-lowering therapy (ULT) within one week prior to the visit to prevent bias in sUA measurements, as well as patients with MSU volumes $< 0.01 \text{ cm}^3$, which may represent artifacts rather than actual urate deposits.

3.2. Grouping Definition

The American College of Rheumatology guidelines recommend maintaining sUA levels below 360 $\mu\text{mol/L}$ (6 mg/dL) for patients on urate-lowering therapy (ULT) (8, 12). Studies have shown associations between sUA levels and various gout-related comorbidities (13). Research by Arthur Shiyovich *et al.* identified that serum urate levels $\geq 9.0 \text{ mg/dL}$ in males are linked to adverse outcomes in diabetic patients (14). Therefore, sUA levels were categorized into three groups: $\geq 9.0 \text{ mg/dL}$, $6.0 - 9.0 \text{ mg/dL}$, and $< 6.0 \text{ mg/dL}$.

According to the Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease, GFR was classified as $\geq 90 \text{ mL/min/1.73 m}^2$ (normal/high) or $< 90 \text{ mL/min/1.73 m}^2$ (declined) (15). Additionally, we employed a volume threshold of 1 cm^3 for MSU crystals, as established by Tristan Pascart *et al.*, which identified factors such as gout duration, diabetes mellitus, and chronic heart failure as significantly associated with MSU volumes $\geq 1 \text{ cm}^3$ (5). This threshold holds clinical significance and may provide predictive insights into gout attacks and related comorbidities.

3.3. Dual-Energy Computed Tomography Assessments

All subjects underwent DECT scans using a SOMATOM Definition Flash CT Scanner, scanning the feet/ankles, knees, and hands/wrists bilaterally. Tube A was operated at 140 kV/115 reference mAs with a 0.6 mm tin filter, while Tube B was operated at 80 kV/210 reference mAs.




Figure 1. A flow chart for study population selection



Figure 2. Dual-energy CT reconstruction of bilateral wrists/hands, knees, and ankles/feet in a 54-year-old patient with a gout duration of 10 years. After excluding of nail bed skin, and beam hardening artifacts, the numbers displayed on the top of the images indicated the volume quantification of monosodium urate crystal. Monosodium urate crystal deposition is color-coded as green.

Detector collimation was set at 64×0.6 mm, and the rotation time was 1.0 second. The MSU deposits were visualized and color-coded using Syngo.via software (version VB 10B; Siemens Healthineers). Volume measurements were automated with the Syngo Dual Energy Gout software, excluding certain artifacts. The urate ratio was set to 1.36, and the smoothing range was set at 4. Fluid was set to a minimum of 150 Hounsfield units for the 80 kV/Sn140 kV images. Total MSU volume was calculated by summing measurements from each site (Figure 2).

3.4. Statistical Analysis

All statistical analyses were conducted using SPSS version 26 (IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp.). Normality was assessed with the Shapiro-Wilk and

Kolmogorov-Smirnov tests, confirming a non-normal distribution of the data. Clinical characteristics were summarized using median and interquartile range (IQR). The Spearman correlation test was employed to evaluate associations between MSU crystal volume and SUA as well as GFR. All tests were two-tailed, with $P < 0.05$ considered statistically significant.

4. Results

Patient demographics and characteristics are summarized in Table 1. Among 527 patients with positive DECT urate deposition, 497 were male, with a median age of 49.0 years and a median gout duration of 6.0 years. Monosodium urate crystals were predominantly deposited in the feet/ankles (84.8%), followed by the knees (63.6%) and hands/wrists (28.8%). The median MSU

Table 1. Demographic and Clinical Characteristics in Imaging Population ^a

| Variables | Ankles/feet (n = 447, 84.8%) | Knees (n = 335, 63.6%) | Hands/wrists (n = 152, 28.8%) | Total (n = 527) |
|---------------------------|------------------------------|------------------------|-------------------------------|-----------------|
| Age, y | 49.0 (24.0) | 50.0 (23.0) | 51.0 (24.0) | 49.0 (23.0) |
| Male, No. (%) | 425 (95.1) | 318 (94.9) | 143 (94.1) | 497 (94.3) |
| Duration, y | 7.0 (6.0) | 8.0 (6.0) | 8.0 (5.0) | 6.0 (6.8) |
| Laboratory results | | | | |
| GFR, mL/min | 95.9 (39.2) | 96.0 (45.4) | 88.0 (32.6) | 97.3 (42.1) |
| GFR ≥ 90 | 111.5 (28.6) | 115.5 (23.3) | 116.9 (24.4) | 111.9 (27.7) |
| GFR < 90 | 69.8 (26.2) | 30.0 (44.0) | 66.2 (15.3) | 69.7 (26.2) |
| sUA, mg/dL | 9.4 (3.2) | 9.4 (3.3) | 9.9 (3.6) | 9.4 (3.4) |
| sUA ≥ 9.0 | 10.6 (1.8) | 10.8 (2.0) | 11.0 (2.1) | 10.7 (1.9) |
| 9.0 > sUA ≥ 6.0 | 7.8 (1.2) | 7.9 (1.3) | 7.9 (0.6) | 7.7 (1.2) |
| sUA < 6.0 | 5.2 (1.0) | 5.2 (1.3) | 5.5 (0.5) | 5.2 (1.2) |
| MSU, cm ³ | 0.5 (3.9) | 1.2 (5.7) | 0.8 (4.1) | 15.6 (55.5) |

Abbreviations: GFR, glomerular filtration rate; sUA, serum urate; MSU, monosodium urate.

^aValues are expressed as medians, with inter-quartile ranges in parentheses unless otherwise indicated.**Table 2.** Association Between Clinical and Laboratory Parameters and Monosodium Urate Volume in Different Joints ^a

| Variables | Ankles/feet (n = 447) | Knees (n = 335) | Hands/wrists (n = 152) | Total volumes (n = 527) | Number of MSU deposition regions |
|------------------------------|-----------------------------|----------------------------|----------------------------|-----------------------------|----------------------------------|
| sUA, mg/dL (n = 308) | 0.06 (0.52) | 0.06 (0.41) | -0.14 (0.17) | 0.08 (0.16) | 0.11 (0.07) |
| sUA ≥ 9.0 (n = 171) | 0.07 (0.38) | 0.04 (0.66) | -0.15 (0.24) | 0.05 (0.51) | 0.09 (0.22) |
| 9.0 > sUA ≥ 6.0 (n = 100) | -0.01 (0.94) | -0.03 (0.83) | 0.17 (0.41) | 0.06 (0.56) | 0.13 (0.21) |
| sUA < 6.0 (n = 37) | 0.18 (0.33) | -0.02 (0.92) | 0.09 (0.78) | 0.09 (0.59) | 0.22 (0.19) |
| Duration, y (n = 432) | 0.30 (< 0.01) ^b | 0.25 (< 0.01) ^b | 0.26 (< 0.01) ^b | 0.32 (< 0.01) ^b | 0.33 (< 0.01) ^b |
| Duration ≥ 10 (n = 161) | 0.19 (0.02) ^b | 0.20 (0.03) ^b | -0.14 (0.33) | 0.21 (< 0.01) ^b | 0.25 (< 0.01) ^b |
| Duration < 10 (n = 271) | 0.19 (< 0.01) ^b | 0.20 (0.01) ^b | 0.25 (0.03) ^b | 0.29 (< 0.01) ^b | 0.32 (< 0.01) ^b |
| GFR, mL/min (n = 273) | -0.18 (< 0.01) ^b | -0.16 (0.03) ^b | -0.06 (0.55) | -0.17 (< 0.01) ^b | -0.14 (0.02) ^b |
| GFR ≥ 90 (n = 163) | 0.01 (0.99) | -0.03 (0.72) | 0.03 (0.87) | -0.02 (0.78) | -0.04 (0.64) |
| GFR < 90 (n = 110) | -0.13 (0.20) | -0.06 (0.63) | -0.06 (0.66) | -0.14 (0.15) | -0.15 (0.13) |

Abbreviations: sUA, serum urate; GFR, glomerular filtration rate; MSU, monosodium urate.

^aValues are the correlation coefficients with P-values in parentheses.^bValues indicate statistically significant correlations (P < 0.05).

crystal volumes were larger in the knees (1.2 cm³) compared to the hands/wrists (0.5 cm³) and feet/ankles (0.8 cm³).

The correlation between various clinical characteristics and MSU volumes is detailed in Tables 2 and 3. A significant correlation was observed between gout duration (categorized into two groups: ≥ 10 years and < 10 years) and MSU crystal volumes in the feet/ankles [$r = 0.19$ (95% CI: 0.015, 0.355), $P = 0.02$; $r = 0.19$ (95% CI: 0.061, 0.309), $P < 0.01$, respectively], knees [$r = 0.20$ (95% CI: -0.003, 0.388), $P = 0.03$; $r = 0.20$ (95% CI: 0.047, 0.349), $P = 0.01$, respectively], total volumes [$r = 0.21$ (95% CI: 0.052, 0.372), $P < 0.01$; $r = 0.29$ (95% CI: 0.173,

0.391), $P < 0.01$, respectively], and the number of MSU deposition regions [$r = 0.25$ (95% CI: 0.092, 0.406), $P < 0.01$; $r = 0.32$ (95% CI: 0.212, 0.424), $P < 0.01$, respectively].

Regarding GFR, a significant correlation was found between GFR and MSU volume in the feet/ankles, knees, total MSU volume, and the number of MSU deposition regions [$r = -0.18$ (95% CI: -0.351, -0.072), $P < 0.01$; $r = -0.17$ (95% CI: -0.284, -0.052), $P < 0.01$; $r = -0.14$ (95% CI: -0.252, -0.013), $P = 0.02$, respectively]. However, no statistically significant correlation was observed between GFR and MSU volume in the hands/wrists [$r = -0.06$ (95% CI: -0.274, 0.142), $P = 0.55$]. Furthermore, no significant correlations were found when comparing the three GFR groups using cutoff values of 90 mL/min and 60 mL/min

Table 3. Association Between Monosodium Urate Volume and Clinical and Laboratory Parameters in Different Monosodium Urate Volume Groups

| Characteristics | MSU $\geq 1 \text{ cm}^3$ (n = 241) | MSU $< 1 \text{ cm}^3$ (n = 285) | MSU volume at feet/ankles $\geq 1 \text{ cm}^3$ (n = 184) | MSU volume at feet/ankles $< 1 \text{ cm}^3$ (n = 263) |
|----------------------------------|-------------------------------------|----------------------------------|---|--|
| sUA, mg/dL | -0.05 (0.55) | -0.04 (0.63) | 0.03 (0.72) | 0.06 (0.52) |
| sUA ≥ 9.0 | -0.02 (0.84) | -0.17 (0.13) | 0.05 (0.66) | -0.002 (0.98) |
| 9.0 > sUA ≥ 6.0 | -0.02 (0.89) | 0.06 (0.68) | 0.13 (0.40) | -0.04 (0.81) |
| sUA < 6.0 | 0.25 (0.42) | -0.28 (0.18) | 0.32 (0.29) | -0.31 (0.22) |
| Duration, y | 0.25 (< 0.01) ^b | 0.21 (< 0.01) ^b | 0.21 (0.01) ^b | 0.13 (0.049) ^b |
| Duration ≥ 10 | 0.18 (0.08) | -0.03 (0.82) | 0.15 (0.18) | -0.04 (0.76) |
| Duration < 10 | 0.22 (0.02) ^b | 0.21 (< 0.01) ^b | 0.27 (0.02) ^b | 0.04 (0.59) |
| GFR, mL/min | -0.25 (< 0.01) ^b | -0.04 (0.62) | -0.15 (0.12) | 0.01 (0.89) |
| GFR ≥ 90 | -0.01 (0.93) | -0.07 (0.56) | -0.006 (0.97) | -0.05 (0.64) |
| GFR < 90 | -0.08 (0.53) | 0.18 (0.22) | -0.01 (0.94) | 0.41 (< 0.01) ^b |
| Number of MSU deposition regions | 0.54 (< 0.01) ^b | 0.47 (< 0.01) ^b | 0.44 (< 0.01) ^b | 0.34 (< 0.01) ^b |

Abbreviations: sUA, serum urate; GFR, glomerular filtration rate; MSU, monosodium urate.

^a Values are the correlation coefficients with P-values in parentheses.

^b Values indicate statistically significant correlations (P < 0.05).

with MSU volume in the feet/ankles, knees, hands/wrists, total MSU volume, and the number of MSU deposition regions. Additionally, no statistically significant correlation was observed between MSU volumes and sUA levels across all groups.

Table 3 further supports the lack of significant correlations between sUA groups and MSU volume categories, consistent with the findings in **Table 2**. However, statistically significant correlations were observed between gout duration and the number of MSU deposition regions across the four MSU volume groups. The highest correlation coefficient was observed in cases where MSU crystal volume was $\geq 1 \text{ cm}^3$ [$r = 0.54$ (95% CI: 0.443, 0.632), $P < 0.01$].

For patients with gout duration < 10 years, significant correlations were found between MSU volume and the four volume groups (except for MSU volume in the feet $< 1 \text{ cm}^3$), with correlation coefficients exceeding 0.20, reaching a maximum of 0.27 in the MSU volume at feet $\geq 1 \text{ cm}^3$ group. Additionally, a significant negative correlation was identified between the MSU $\geq 1 \text{ cm}^3$ group and total GFR [$r = -0.25$ (95% CI: -0.398, -0.099), $P < 0.01$].

5. Discussion

In this study, we identified a significant relationship between GFR and MSU crystal burden across various deposition sites, including the feet/ankles, knees, total MSU volumes, and the number of MSU deposition

regions. Additionally, disease duration was significantly correlated with MSU volumes in different joints. However, no statistical association was observed between MSU volumes and sUA levels across the three defined ranges ($\geq 9.0 \text{ mg/dL}$, $6.0 - 9.0 \text{ mg/dL}$, and $< 6.0 \text{ mg/dL}$). These findings support our study's objective of examining the relationships between clinical characteristics and MSU burden.

Our analysis did not reveal a statistically significant correlation between total sUA levels or the three predefined sUA ranges and MSU volumes or deposition sites, which is consistent with the findings of Pascart *et al.* (5). This suggests that MSU deposition can occur even in individuals with hyperuricemia. Prior DECT studies have also reported weak correlations between MSU deposits and sUA levels (16). These results emphasize that sUA levels do not accurately reflect MSU burden in gout patients, reinforcing the notion that MSU crystal deposition is the central pathology rather than elevated sUA levels alone. Consequently, gout management strategies that rely solely on sUA monitoring may be inadequate. Our findings indicate that the presence of MSU deposits is not necessarily associated with persistently elevated sUA levels, suggesting that hyperuricemia is neither a sufficient nor a necessary condition for MSU crystal deposition.

Additionally, our study confirms that disease duration significantly influences MSU deposition, as demonstrated by a positive correlation between gout duration and MSU volumes in multiple joints. This aligns with Pascart *et al.*'s findings, which also reported

a correlation between DECT-measured MSU crystal volumes and gout duration (5). We further observed a significant association between MSU volumes in the wrists/hands and disease duration, although this correlation weakened after 10 years. This suggests that MSU deposition in the wrists and hands may not increase linearly with disease progression, possibly due to delayed joint involvement and the effects of therapeutic interventions over time.

We propose that specific comorbidities contribute to MSU deposition independently of sUA levels. Normal sUA levels during gout flares may result from enhanced renal excretion. Gout and hyperuricemia are strongly associated with CKD, while CKD itself is an independent risk factor for gout (17). The MSU crystal deposition primarily arises from elevated urate concentrations due to impaired renal or gut excretion rather than urate overproduction. Our findings demonstrated a significant negative correlation between MSU volumes in the feet/ankles, knees, total MSU burden, and the number of MSU deposition regions with GFR. Previous studies have shown that patients with tophaceous gout exhibit lower GFR, suggesting that MSU deposition may serve as an indicator of renal function (18). Notably, we found a significant correlation between total MSU volume ($\geq 1 \text{ cm}^3$) and total GFR (Table 3). These findings suggest that regression of MSU crystals in the feet/ankles and knees, as well as a reduction in total MSU burden ($\geq 1 \text{ cm}^3$), during urate-lowering therapy (ULT) may lead to improved renal function and a reduced risk of CKD.

This study has several limitations. First, it was a single-center retrospective review with only 37 patients having sUA levels below 6.0 mg/dL, which may introduce selection bias. Additionally, incomplete treatment profiles and potential confounding factors, such as age, gender, and comorbidities, were not accounted for in the analysis. Future studies should incorporate these variables to provide a more comprehensive understanding of MSU deposition and its clinical implications.

In conclusion, this study demonstrated that MSU volumes correlate significantly with GFR levels but not with sUA levels. With the exception of MSU volumes in the hands/wrists for patients with over ten years of disease duration, MSU deposition in the feet/ankles, knees, total MSU burden, and number of deposition regions was associated with both disease duration and renal function in gout patients. Understanding these relationships can aid clinicians in predicting disease

progression, optimizing urate-lowering therapies, and implementing early interventions to mitigate CKD risk.

Footnotes

Authors' Contribution: Study concept and design: H. W. and J. Z.; Analysis and interpretation of data: J. Z. and L. L.; Drafting of the manuscript: J. Z. and L.L.; Critical revision of the manuscript for important intellectual content: H. W.; Statistical analysis: J. Z., L. L., Y. Z., and Y. Z.; Technical support: L. C.

Conflict of Interests Statement: One of the authors of this manuscript L. C. is an employee of Siemens, but he was not involved in the analysis of the data and had no control of data or information submitted for publication. Dr. J. Z. and Dr. L. L. contributed equally to this work and we request Dr. L. L. should be listed as Common First Author. All authors have read and approved this version of the article. No conflict of interest exists in the submission of the manuscript. All patients in our study have never been reported before and without any subject overlap in the current manuscript.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication. The data are not publicly available due to the hospital's data security management policy.

Ethical Approval: This retrospective cross-sectional study was approved by the ethics committee of Guangdong Provincial people's hospital (ID: S2024-058-01).

Funding/Support: This study was supported in part by grant 2021A1515011571 from the Natural Science Foundation of Guangdong Province.

Informed Consent: Written informed consent was obtained.

References

1. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. *Lancet*. 2021;397(10287):1843-55. [PubMed ID: 33798500]. [https://doi.org/10.1016/S0140-6736\(21\)00569-9](https://doi.org/10.1016/S0140-6736(21)00569-9).
2. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. *Nat Rev Rheumatol*. 2020;16(7):380-90. [PubMed ID: 32541923]. <https://doi.org/10.1038/s41584-020-0441-1>.
3. Dalbeth N, House ME, Aati O, Tan P, Franklin C, Horne A, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. *Ann Rheum Dis*.

2015;74(5):908-11. [PubMed ID: 25637002]. <https://doi.org/10.1136/annrheumdis-2014-206397>.

4. Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review. *BMC Musculoskelet Disord.* 2015;16:296. [PubMed ID: 26467213]. [PubMed Central ID: PMC4606994]. <https://doi.org/10.1186/s12891-015-0762-4>.

5. Pascart T, Ramon A, Ottaviani S, Legrand J, Ducoulombier V, Houvenagel E, et al. Association of Specific Comorbidities with Monosodium Urate Crystal Deposition in Urate-Lowering Therapy-Naïve Gout Patients: A Cross-Sectional Dual-Energy Computed Tomography Study. *J Clin Med.* 2020;9(5). [PubMed ID: 32369943]. [PubMed Central ID: PMC7288279]. <https://doi.org/10.3390/jcm9051295>.

6. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. *Arthritis Res Ther.* 2015;17(1):90. [PubMed ID: 25889144]. [PubMed Central ID: PMC4404569]. <https://doi.org/10.1186/s13075-015-0610-9>.

7. Stack AG, Johnson ME, Blak B, Klein A, Carpenter L, Morlock R, et al. Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study. *BMJ Open.* 2019;9(8). e031550. [PubMed ID: 31462487]. [PubMed Central ID: PMC6720233]. <https://doi.org/10.1136/bmjopen-2019-031550>.

8. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken).* 2012;64(10):1431-46. [PubMed ID: 23024028]. [PubMed Central ID: PMC3683400]. <https://doi.org/10.1002/acr.21772>.

9. Ogdie A, Taylor WJ, Weatherall M, Fransen J, Jansen TL, Neogi T, et al. Imaging modalities for the classification of gout: systematic literature review and meta-analysis. *Ann Rheum Dis.* 2015;74(10):1868-74. [PubMed ID: 24915980]. [PubMed Central ID: PMC4869978]. <https://doi.org/10.1136/annrheumdis-2014-205431>.

10. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol.* 2006;17(10):2937-44. [PubMed ID: 16988059]. <https://doi.org/10.1681/ASN.2006040368>.

11. Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis.* 2015;74(10):1789-98. [PubMed ID: 26359487]. [PubMed Central ID: PMC4602275]. <https://doi.org/10.1136/annrheumdis-2015-208237>.

12. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. *Arthritis Care Res (Hoboken).* 2012;64(10):1447-61. [PubMed ID: 23024029]. [PubMed Central ID: PMC3662546]. <https://doi.org/10.1002/acr.21773>.

13. Mortada I. Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association. *Curr Hypertens Rep.* 2017;19(9):69. [PubMed ID: 28770533]. <https://doi.org/10.1007/s11906-017-0770-x>.

14. Shiyovich A, Gilutz H, Plakht Y. Serum electrolyte/metabolite abnormalities among patients with acute myocardial infarction: comparison between patients with and without diabetes mellitus. *Postgrad Med.* 2021;133(4):395-403. [PubMed ID: 33275496]. <https://doi.org/10.1080/00325481.2020.1860393>.

15. Kidney Disease: Improving Global Outcomes CG. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int.* 2024;105(4S):S117-314. [PubMed ID: 38490803]. <https://doi.org/10.1016/j.kint.2023.10.018>.

16. Rajan A, Aati O, Kalluru R, Gamble GD, Horne A, Doyle AJ, et al. Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study. *Arthritis Res Ther.* 2013;15(5):R160. [PubMed ID: 24286500]. [PubMed Central ID: PMC3978645]. <https://doi.org/10.1186/ar4343>.

17. Wang W, Bhole VM, Krishnan E. Chronic kidney disease as a risk factor for incident gout among men and women: retrospective cohort study using data from the Framingham Heart Study. *BMJ Open.* 2015;5(4). e006843. [PubMed ID: 25869687]. [PubMed Central ID: PMC4401834]. <https://doi.org/10.1136/bmjopen-2014-006843>.

18. Lawrence Edwards N, Singh JA, Troum O, Yeo AE, Lipsky PE. Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase. *Rheumatol (Oxford).* 2019. [PubMed ID: 30843588]. <https://doi.org/10.1093/rheumatology/kez017>.